AB046. Potential application of adipose derived stem cells for urological disease

Adipose derived stem cells (ADSCs) are a somatic stem cell population contained in fat tissue that may benefit the recovery of urological disease by using a stem cell based therapy. ADSCs have previously been shown to possess stem cell properties such as transdifferentiation and self-renewal, which are a somatic stem cell population contained in fat tissue. ADSCs share the same properties of all stem cells, such as the ability to divide and renew themselves for long periods, and differentiate into specialized cells. Similar to other kinds of MSC, ADSC express multiple CD marker antigens (CD73+ CD90+ CD105+ CD34+/- CD11b- CD104b- CD19- CD31- CD45- SMA-). Meanwhile, the ADSCs have many advantages, including the ability to isolate many more stem cells using a minimally invasive surgical procedure for extraction of the adipose tissue. Available evidence concerning adipose derived stem cell availability, differentiation into functional cells, and the potential of these cells were examined the current data (from 1964 to 2014) associated with the definition, characterization, differentiation, and application of adipose derived stem cells for the cell-based therapies of urological diseases. The adipose-derived stem cells are regarded as candidates for the treatment of urological diseases due to many factors. These stem cells can easily be obtained in large quantities and possess the potential to undergo long-term proliferation, self-renewal and multipotent differentiation. There is strong evidence supporting the concept that ADSCs may be a potential stem cell therapy source for urological diseases.